1.06 AE 0.12; mean postdilation balloon diameter 3.26 AE 0.44mm; mean maximal postdilation pressure: 16.05 AE 4.24mmhg). Baseline clinical characteristics were similar between the PD and non-PD groups. The left anterior descending artery (47.8%) was the most commonly treated vessel in the study population. Lesion complexity and calcification were higher in the PD group (AHA B2/C lesion: 48.4% in PD vs 24.5% in non-PD, p < 0.001; Moderate/heavy calcification: 51.2% vs 29.6%, p<0.001). Treatment length was significantly longer in PD compared to non-PD (25.31 AE14.53 vs 20.06 AE10.13, p<0.001). Lesion preparation (percentage predilation performed and pre B:A ratio) was similar between the PD and non-PD groups. Acute lumen gain was significantly decreased in PD compared to non-PD (1.33 AE0.59 vs 1.53 AE0.63mm, p¼ 0.002). From QCA, PD resulted in a significant increase in reference vessel diameter (RVD, 0.16 AE 0.37, p< 0.001), minimal lumen diameter (MLD: 0.14 AE 0.32mm, p < 0.001) and non-significant decrease in diameter stenosis [%DS: (-)0.03 AE 12.39%, p¼ 0.976] after BRS implantation. Overall device success rates was 99.5% and allcause mortality occurred in 2.7% of the study population with no differences between the PD and non-PD groups. Other clinical outcomes are currently being adjudicated and would be available on presentation.
CONCLUSIONS In our study, while PD resulted in a marginal increase in RVD and MLD after BRS implantation, acute lumen gain was smaller in the PD group and short term procedural outcome and mortality remained similar between the 2 groups. METHODS Eighteen Absorb BVS were implanted in main coronary arteries of healthy Yucatan mini Swine. Transmission electron microscopy was performed at seven time points from 28-days to 48-months. Ultrastructural changes of polymeric struts / resorption sites (RS, > 36 months) were morphologically characterized.
RESULTS Up to 12-months, struts were intact with surrounding macrophages and fibroblasts. The PDLLA polymer coating was observed as a black line of calcified material (A) as thinly separated from the strut polymer. Collagen deposition was seen along the surfaces with acellular cytoplasmic processes extending into the strut surface from the surrounding cellular area (B & C). At 24-months the acellular processes extended deeper into the strut surface. Collagen and smooth muscle cells bordered the strut. At 30-months, some strut surfaces remained intact with surrounding dense collagen and fibroblasts (B) while other areas shows superficial polymer microfragmentation (A & C). Internally, struts appeared sparsely granular. At 36-months RS were tightly surrounded by fibrous tissue (B). Cellular and collagen-proteoglycan ingrowth subdivided RS, which show more dense granularity than at 30 months (A & C). At 42-and 48-months, RS were reduced to multiple amorphous, densely granular particles subdivided and surrounded by collagen and proteoglycan rich matrix with myofibroblasts and interspersed calcified material.
CONCLUSIONS Our investigation reveals the nature of the changes seen within the polymeric struts. As polymer resorbs (30 -36 months) it shows increasing granularity (nonfibrellar glycoprotein) with eventual replacement by a proteinceous matrix with integrated collagen and myofibroblasts at 48-months. 5 Pozna n University School of the Medical Sciences, Pozna n, Poland BACKGROUND The data concerning the use of bioresorbable vascular scaffolds (BVS) in coronary bifurcation lesions are limited. Given the complexity of the procedure and the potential risk of struts' damage it is imperative to evaluate the efficacy and long-term safety of BVS in such lesions. The aim of the study was to evaluate the early and longterm clinical outcomes of bifurcation stenting with BVS.
METHODS The study is a prospective, nonrandomized clinical registry of patients with coronary bifurcation lesion treated with everolimuseluting BVS. Sixty consecutive patients, with stable coronary artery disease or acute coronary syndromes were enrolled. The study excluded patients with concomitant serious illnesses, those who were unable to receive prolonged dual antiplatelet therapy or required chronic oral anticoagulation therapy. Bifurcation lesion was defined and classified according to European Bifurcation Club definition and Medina classification. The main clinical study end point was a deviceoriented target lesion failure (TLF), defined as the combination of cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularization.
RESULTS Sixty consecutive patients (male 71.7%, mean age 62.6AE11.2 years) were included, 18 of them had diabetes mellitus (30%) and 10 chronic kidney disease (17%). True bifurcation lesion was found in 27 patients (45%). Nine lesions (15%) comprised the left main coronary artery. On QCA the mean proximal and distal main vessel reference diameters were 3.12 AE 0.36 mm and 2.65 AE 0.43 mm respectively, whereas the mean lesion length and diameter stenosis were 12.73 AE 9.53 mm and 69.72 AE 27.33 mm. The mean side branch (SB) reference diameter was 2.34 AE 0.36 mm, SB lesion length 5.66 AE 5.27 mm, and lesion diameter stenosis 44.58AE 27.47%. A total of 71 BVS were implanted. Provisional T stenting was performed in 42 patients (70%), distal main vessel stenting in one patient, systematic T stenting in 6 (10%), and T with minimal protrusion (TAP) in 2 patients (2.2%). SB ostial stenting was performed in additional 9 patients (15%). The final 
